Global Rheumatology Therapeutics Market 2023-2030

Global Rheumatology Therapeutics Market 2023-2030

Global Rheumatology Therapeutics Market Size, Share & Trends Analysis Report by Drug Type (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs and Others), by Disease Indication (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, and Ankylosing Spondylitis), by Category (Prescription and Over-the-Counter (OTC), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), Forecast Period (2023-2030)

The global market is anticipated to grow at a CAGR of 3.2% during the forecast period (2023-2030). Therapeutic drugs are used to slow down the progression of certain autoimmune rheumatic diseases such as rheumatic arthritis (RA). The increasing prevalence of RA globally has bolstered the launch of novel therapeutic agents and favorable refurbishment policies for high-cost treatment products are some of the factors driving the market growth. According to the National Institute of Health (NIH), in May 2023, rheumatic arthritis is more prevalent in women compared to men, with a lifetime risk of rheumatic arthritis of 3.6% in women compared to 1.7% in men. RA risk also increases with age, with a peak incidence between age 65 to 80 years of age. Furthermore, the rise in the rate of launches of novel biologics drugs, increasing approvals and growing penetration of generic drugs extend profitable opportunities to the rheumatology therapeutics market. For instance, in June 2022, Amgen announced that FDA approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

Segmental Outlook

The global rheumatology therapeutics market is segmented on the drug type, disease indication, category, and distribution channel. Based on the drug type, the market is sub-segmented into disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs and others. Based on the disease indication, the market is sub-segmented into rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, and ankylosing spondylitis. Based on the category, the market is bifurcated into prescription and OTC. Furthermore, on the basis of distribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy and online pharmacy. Among the disease indication, the rheumatoid arthritis sub-segment is anticipated to hold a considerable share of the market owing to the development of novel technologies such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-based genome editing, RNA interference, PROTACs (proteolysis-targeted chimeras), and artificial intelligence (AI)-based drug design enable the screening of therapies targeting.

The Disease-modifying Anti-rheumatic Drugs (DMARDs) Sub-Segment is Anticipated to Hold a Considerable Share of the Global Rheumatology Therapeutics Market

Among the drug type, the sub-segment is expected to hold a considerable share of the global rheumatology therapeutics market. The segmental growth is attributed to the increased utilization of DMARD coupled with the rising incidence of RA around the globe. For instance, according to the National Center for Biotechnology Information, in June 2022, the annual incidence of RA in the US and other Western nations of northern Europe is about 40 per 100,000 persons. Owing to a surge in awareness related to treatment options available for RA.

Regional Outlook

The global rheumatology therapeutics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market, owing to the increasing prevalence of rheumatoid arthritis, increasing awareness about the disorder, and increasing prevalence combined with the adoption of advanced rheumatoid arthritis therapeutics is expected to drive market growth. The key market player includes Chugai Pharmaceutical Co., Ltd., Dr Reddy's Laboratories Ltd. LG Chem, Lupin Ltd, Taisho Pharmaceutical Holdings Co., Ltd., and others.

The North America Region is Expected to Grow at a Significant CAGR in the Global Rheumatology Therapeutics Market

Among all regions, the North America region is anticipated to grow at a considerable CAGR over the forecast period. The regional market growth is attributed to the growing awareness regarding the early diagnosis and treatment of rheumatology disease and the increasing use of DMARD’s for treating. Furthermore, the rise in launches of novel biologics drugs, increasing approvals and growing penetration of generic drugs extend profitable opportunities to the rheumatology therapeutics market players. For instance, in July 2023, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd., announced that after 5 years of use in Europe and two years in Canada, HULIO® (adalimumab-fkjp) injectable, a biosimilar to Humira® (adalimumab), is now accessible to patients in the US.

Market Players Outlook

The major companies serving the global rheumatology therapeutics market include F. Hoffmann-La Roche Ltd., Johnson & Johnson Private Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2023, Gilead Sciences, Inc. and EVOQ Therapeutics, Inc. collaborated along with a licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ’s NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases.

The Report Covers

Market value data analysis of 2022 and forecast to 2030.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global rheumatology therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.